Sanofi Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Sanofi ha aumentado sus beneficios a una tasa media anual de 5.5%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 1.7% anual. Los ingresos han ido creciendo a una tasa media de 5.7% al año. La rentabilidad financiera de Sanofi es de 6.2%, y sus márgenes netos son de 9.8%.

Información clave

5.5%

Tasa de crecimiento de los beneficios

5.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	5.7%
Rentabilidad financiera	6.2%
Margen neto	9.8%
Próxima actualización de resultados	25 Jul 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Sanofi. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:SNY Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	46,288	4,538	10,763	6,884
31 Dec 23	46,033	5,400	10,765	6,728
30 Sep 23	45,699	9,066	10,703	6,679
30 Jun 23	46,045	8,617	10,783	6,752
31 Mar 23	46,199	8,357	10,767	6,780
31 Dec 22	45,389	8,371	10,539	6,706
30 Sep 22	44,348	6,409	10,399	6,468
30 Jun 22	42,039	6,643	10,025	6,176
31 Mar 22	40,342	6,666	9,784	5,914
31 Dec 21	39,175	6,223	9,599	5,692
30 Sep 21	38,496	6,174	9,457	5,622
30 Jun 21	37,546	5,777	9,362	5,501
31 Mar 21	36,939	12,197	9,301	5,455
31 Dec 20	37,369	12,294	9,448	5,530
30 Sep 20	37,650	11,224	9,613	5,699
30 Jun 20	37,692	11,138	9,729	5,738
31 Mar 20	38,234	3,453	9,936	5,973
31 Dec 19	37,631	2,855	9,967	6,020
30 Sep 19	36,940	3,179	9,951	6,010
30 Jun 19	36,763	3,591	9,959	6,111
31 Mar 19	36,264	4,439	9,998	5,999
31 Dec 18	35,677	4,319	9,934	5,894
30 Sep 18	35,316	4,041	9,906	5,680
30 Jun 18	34,985	3,243	9,918	5,560
31 Mar 18	35,428	3,539	9,980	5,443
31 Dec 17	36,221	3,773	10,164	5,472
30 Sep 17	36,400	4,593	10,077	5,445
30 Jun 17	36,315	4,744	10,034	5,325
31 Mar 17	35,677	4,682	9,866	5,246
31 Dec 16	34,696	4,395	9,592	5,172
30 Sep 16	34,349	4,195	9,479	5,099
30 Jun 16	34,115	4,154	9,452	5,191
31 Mar 16	34,569	4,440	9,458	5,158
31 Dec 15	34,861	4,411	9,496	5,082
30 Sep 15	37,201	5,292	10,154	5,195
30 Jun 15	32,910	4,628	8,873	4,745
31 Mar 15	35,074	4,329	9,609	4,884
31 Dec 14	31,999	4,273	8,565	4,667
30 Sep 14	33,484	4,112	8,945	4,719
30 Jun 14	33,134	4,140	8,640	4,755
31 Mar 14	33,074	3,812	8,699	4,752
31 Dec 13	31,291	3,639	8,107	4,605
30 Sep 13	33,424	3,127	8,824	4,895
30 Jun 13	34,146	3,364	9,153	4,840

Ingresos de calidad: SNY tiene un gran one-off loss de €2.0B impacto en sus últimos 12 meses de resultados financieros a 31st March, 2024.

Margen de beneficios creciente: Los actuales márgenes de beneficio(9.8%) de SNY son inferiores a los del año pasado (18.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de SNY han crecido un 5.5% al año en los últimos 5 años.

Acelerando crecimiento: SNY ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: SNY tuvo un crecimiento negativo de los beneficios (-45.7%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (-6.8%).

Sanofi Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Recent updates

Sanofi Q1: Wait And See For Now (Downgrade)

Sanofi Announces Board and Committee Appointments

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi: My Top Pick In Big Pharma

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi Reiterates Earnings Guidance for the Year 2023

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Sanofi Provides Earnings Guidance for the Year 2023

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta